Variable
|
Controls
(n=10) |
Patients
(n=30) |
Age(years)
|
54.22 ± 5.2
|
55.60 ± 5.5 |
Male / Female (%) |
60 / 40 |
56.7/ 43.3 |
Smokers / non-smokers (%) |
60/ 40 |
53.3 / 46.7 |
Staging (%)
Stage IIA
Stage IIB
Stage III |
---
---
-- |
33.3
43.4
23.3 |
Histopathological type (%)
Squamous cell carcinoma
Adenocarcinoma
Large cell carcinoma |
----
----
---- |
53.4
23.3
23.3 |
Hb, g/dl, |
12.7± 2.7 |
11.2 ± 2.8 |
RBCs (106/mm3), |
4.6 ± 3. 7 |
4.2 ± 3.9 |
WBCs(103/mm3), |
6.1 ± 3.7 |
13.5 ± 3.2** |
Platelet (103/mm3), |
233 ± 3.1 |
338 ± 2.2** |
ESR(1h/ 2h) |
5.2 ± 2.7/10.7 ± 2.2
|
77.6 ± 6.7/ 107±5.78** |
Serum creatinine |
1.01 ± 2.1 |
1.0±1.9 |
Liver function
AST (U/l)
ALT (U/l) |
18.2±3.8
15.02±1. 4 |
18.88±3.4
16.09±1.8 |
|
| Hb=heamoglobin, WBCs= white blood cells, ESR= Erythrocetic sedimentation
rate, AST= alanine spartate, ALT= alanine transferase
*= P<0.5; **=P<0.01 |
| Table 1: Demographic and hematological characteristics of controls and NSCLC
patients before treatment. |
